68Ga-HA-DOTATATE PET/CT in Adults With Neuroendocrine Tumors

RecruitingOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

February 1, 2023

Primary Completion Date

January 1, 2027

Study Completion Date

January 1, 2027

Conditions
Neuroendocrine Tumors (NET)
Interventions
DIAGNOSTIC_TEST

68Ga-HA-DOTATATE PET/CT imaging

"Each patient will receive an IV injection 68Ga-HA-DOTATATE. Imaging will be conducted beginning 45-90 minutes after an injection of between 100-250 MBq 68Ga-HA-DOTATATE in patients.~* After the 68Ga-HA-DOTATATE acquisition is complete, a CT scan will be performed for attenuation correction and localization in the same in line gantry without patient movement between the two scans.~* The results of the 68Ga-HA-DOTATATE PET/CT will be compared to any prior imaging and pathologic results."

Trial Locations (1)

T2N 2T9

RECRUITING

Foothills Medical Center 1403 29 St NW, Calgary

All Listed Sponsors
lead

Alberta Health services

OTHER